- Clinical Trials
- April 2024
- 85 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Report
- March 2024
- 397 Pages
Global
From €7656EUR$7,950USD£6,584GBP
- Report
- September 2018
- 174 Pages
Global
From €1324EUR$1,375USD£1,139GBP
€2648EUR$2,750USD£2,278GBP
Fanapt is a medication used to treat schizophrenia in adults. It is a selective dopamine D2 receptor antagonist, which works by blocking the action of dopamine in the brain. It is used to reduce the symptoms of schizophrenia, such as hallucinations, delusions, and disorganized thinking. Fanapt is also used to treat schizoaffective disorder, a condition that combines features of both schizophrenia and a mood disorder.
The Fanapt market is a subset of the larger mental disorders drugs market. It is a rapidly growing market, driven by the increasing prevalence of mental health disorders and the need for effective treatments. The market is highly competitive, with a number of companies offering similar products.
Some of the companies in the Fanapt market include Novartis, Otsuka Pharmaceuticals, and Sunovion Pharmaceuticals. Show Less Read more